Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

Corona Remedies introduces affordable generic version of empagliflozin for type 2 diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:50 Hrs [IST] Corona Remedies Limited ha ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

While the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Type 2 diabetes is a global health challenge affecting more than 400 million adults. While it is often seen as a lifelong ...